Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9372289 | Current Paediatrics | 2005 | 9 Pages |
Abstract
Duchenne muscular dystrophy (DMD) is an X-linked disorder for which there is currently no curative treatment. The natural history is such that affected boys need to use a wheelchair at around 9 years, develop respiratory and cardiac complications and die at a mean age of 19 years. While treatments based on gene modification or replacement are eagerly awaited, advances in medical management of DMD have made a significant difference to the natural history of the condition such that most affected individuals can now be expected to live into adulthood. The key interventions relate to the use of corticosteroids to improve muscle strength and function, surgical management of scoliosis and surveillance for and timely management of respiratory and cardiac complications. The predictable nature of the complications of DMD lends itself to the implementation of a planned programme of surveillance and management, which makes a real difference to survival and quality of life.
Related Topics
Health Sciences
Medicine and Dentistry
Perinatology, Pediatrics and Child Health
Authors
K. Bushby, J. Bourke, R. Bullock, M. Eagle, M. Gibson, J. Quinby,